Article
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood - 13 Oct 2022
Döhner Hartmut, Wei Andrew H, Roboz Gail J, Montesinos Pau, Thol Felicitas R, Ravandi Farhad, Dombret Hervé, Porkka Kimmo, Sandhu Irwindeep, Skikne Barry, See Wendy L, Ugidos Manuel, Risueño Alberto, Chan Esther T, Thakurta Anjan, Beach C L, Lopes de Menezes Daniel
Abstract excerpt
The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials.gov identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC) who were not candidates for hematopoietic stem cell transplantation. Eligible patients were randomized 1:1 to Oral-AZA 300 mg or placebo for 14 days per 28-day cycle. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.